JP2012520059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520059A5 JP2012520059A5 JP2011551304A JP2011551304A JP2012520059A5 JP 2012520059 A5 JP2012520059 A5 JP 2012520059A5 JP 2011551304 A JP2011551304 A JP 2011551304A JP 2011551304 A JP2011551304 A JP 2011551304A JP 2012520059 A5 JP2012520059 A5 JP 2012520059A5
- Authority
- JP
- Japan
- Prior art keywords
- functional protein
- binding partner
- protein
- item
- peptide mask
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 109
- 108090000623 proteins and genes Proteins 0.000 claims description 109
- 230000027455 binding Effects 0.000 claims description 86
- 239000000758 substrate Substances 0.000 claims description 26
- 229940088598 Enzyme Drugs 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 24
- 108010050904 Interferons Proteins 0.000 claims description 19
- 102000014150 Interferons Human genes 0.000 claims description 19
- 102000005650 Notch Receptors Human genes 0.000 claims description 15
- 108010070047 Notch Receptors Proteins 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- 101700046422 IFNA Proteins 0.000 claims description 11
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 230000001225 therapeutic Effects 0.000 claims description 10
- 102100019633 ST14 Human genes 0.000 claims description 9
- 108010091175 matriptase Proteins 0.000 claims description 9
- 230000036947 Dissociation constant Effects 0.000 claims description 8
- 210000004185 Liver Anatomy 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 210000001519 tissues Anatomy 0.000 claims description 7
- 229920000453 Consensus sequence Polymers 0.000 claims description 6
- 102000004965 antibodies Human genes 0.000 claims description 6
- 108090001123 antibodies Proteins 0.000 claims description 6
- 229940012957 Plasmin Drugs 0.000 claims description 5
- 230000000896 plasminic Effects 0.000 claims description 5
- 102100016263 IFNAR1 Human genes 0.000 claims description 4
- 101710030378 IFNAR1 Proteins 0.000 claims description 4
- 101700067851 MMP9 Proteins 0.000 claims description 4
- 102100006844 MMP9 Human genes 0.000 claims description 4
- -1 HCV-NS3 / 4 Proteins 0.000 claims description 3
- 101710010583 PLAU Proteins 0.000 claims description 3
- 102000031064 asparaginylendopeptidase Human genes 0.000 claims description 3
- 108010055066 asparaginylendopeptidase Proteins 0.000 claims description 3
- 230000001808 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 101710041614 At2g19940 Proteins 0.000 claims description 2
- 150000008574 D-amino acids Chemical class 0.000 claims description 2
- 101700044562 DLL1 Proteins 0.000 claims description 2
- 102100013695 DLL1 Human genes 0.000 claims description 2
- 101700003144 DLL3 Proteins 0.000 claims description 2
- 102100013694 DLL3 Human genes 0.000 claims description 2
- 101700018087 DLL4 Proteins 0.000 claims description 2
- 102100019888 DLL4 Human genes 0.000 claims description 2
- 108010088842 Fibrinolysin Proteins 0.000 claims description 2
- 102100016271 IFNAR2 Human genes 0.000 claims description 2
- 101710030373 IFNAR2 Proteins 0.000 claims description 2
- 101700011451 IFNB1 Proteins 0.000 claims description 2
- 102100015720 IFNB1 Human genes 0.000 claims description 2
- 102100016020 IFNG Human genes 0.000 claims description 2
- 101700086956 IFNG Proteins 0.000 claims description 2
- 102100008685 IFNGR1 Human genes 0.000 claims description 2
- 101710030947 IFNGR1 Proteins 0.000 claims description 2
- 102100013318 IFNLR1 Human genes 0.000 claims description 2
- 101710033966 IFNLR1 Proteins 0.000 claims description 2
- 102000018358 Immunoglobulins Human genes 0.000 claims description 2
- 108060003951 Immunoglobulins Proteins 0.000 claims description 2
- 108010014726 Interferon Type I Proteins 0.000 claims description 2
- 102000002227 Interferon Type I Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 102100006542 JAG1 Human genes 0.000 claims description 2
- 102100006540 JAG2 Human genes 0.000 claims description 2
- 108010047319 Jagged-1 Protein Proteins 0.000 claims description 2
- 108010015743 Jagged-2 Protein Proteins 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 150000001576 beta-amino acids Chemical class 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 102000034327 globular proteins Human genes 0.000 claims description 2
- 108091005889 globular proteins Proteins 0.000 claims description 2
- 108010018844 interferon type III Proteins 0.000 claims description 2
- 108020001756 ligand binding domains Proteins 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims 29
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000033147 ERVK-25 Human genes 0.000 claims 3
- 108091005771 Peptidases Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 108010010648 interferon alfacon-1 Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 51
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000036912 Bioavailability Effects 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 230000035514 bioavailability Effects 0.000 description 2
- 230000000779 depleting Effects 0.000 description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108050005080 Notch Proteins 0.000 description 1
- 102000014736 Notch Human genes 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15473009P | 2009-02-23 | 2009-02-23 | |
| US61/154,730 | 2009-02-23 | ||
| PCT/US2010/025121 WO2010096838A2 (en) | 2009-02-23 | 2010-02-23 | Proproteins and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015146309A Division JP2015193653A (ja) | 2009-02-23 | 2015-07-24 | プロタンパク質およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012520059A JP2012520059A (ja) | 2012-09-06 |
| JP2012520059A5 true JP2012520059A5 (ru) | 2012-12-06 |
| JP5861223B2 JP5861223B2 (ja) | 2016-02-16 |
Family
ID=42634501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011551304A Active JP5861223B2 (ja) | 2009-02-23 | 2010-02-23 | プロタンパク質およびその使用方法 |
| JP2015146309A Pending JP2015193653A (ja) | 2009-02-23 | 2015-07-24 | プロタンパク質およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015146309A Pending JP2015193653A (ja) | 2009-02-23 | 2015-07-24 | プロタンパク質およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (7) | US8399219B2 (ru) |
| EP (1) | EP2398494A4 (ru) |
| JP (2) | JP5861223B2 (ru) |
| CN (1) | CN102481341B (ru) |
| AU (2) | AU2010215761B2 (ru) |
| BR (1) | BRPI1011384A2 (ru) |
| CA (1) | CA2753294A1 (ru) |
| RU (1) | RU2011138951A (ru) |
| WO (1) | WO2010096838A2 (ru) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| WO2010004273A1 (en) | 2008-07-07 | 2010-01-14 | Oxford Nanopore Technologies Limited | Base-detecting pore |
| CN103695530B (zh) | 2008-07-07 | 2016-05-25 | 牛津纳米孔技术有限公司 | 酶-孔构建体 |
| GB0820927D0 (en) | 2008-11-14 | 2008-12-24 | Isis Innovation | Method |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| EP2391655B1 (en) * | 2009-01-30 | 2017-10-11 | Oxford Nanopore Technologies Limited | Hybridization linkers |
| AU2010209528B2 (en) | 2009-01-30 | 2015-10-01 | Oxford Nanopore Technologies Limited | Adaptors for nucleic acid constructs in transmembrane sequencing |
| CA2753294A1 (en) | 2009-02-23 | 2010-08-26 | Cytomx Therapeutics, Inc. | Proproteins and methods of use thereof |
| GB0905140D0 (en) | 2009-03-25 | 2009-05-06 | Isis Innovation | Method |
| WO2012107778A2 (en) | 2011-02-11 | 2012-08-16 | Oxford Nanopore Technologies Limited | Mutant pores |
| AU2012288629B2 (en) | 2011-07-25 | 2017-02-02 | Oxford Nanopore Technologies Limited | Hairpin loop method for double strand polynucleotide sequencing using transmembrane pores |
| US9758823B2 (en) | 2011-10-21 | 2017-09-12 | Oxford Nanopore Technologies Limited | Enzyme method |
| WO2013098561A1 (en) | 2011-12-29 | 2013-07-04 | Oxford Nanopore Technologies Limited | Method for characterising a polynucelotide by using a xpd helicase |
| US10385382B2 (en) | 2011-12-29 | 2019-08-20 | Oxford Nanopore Technologies Ltd. | Enzyme method |
| EP2836506B1 (en) | 2012-04-10 | 2017-04-19 | Oxford Nanopore Technologies Limited | Mutant lysenin pores |
| US11155860B2 (en) | 2012-07-19 | 2021-10-26 | Oxford Nanopore Technologies Ltd. | SSB method |
| CA2879355C (en) | 2012-07-19 | 2021-09-21 | Oxford Nanopore Technologies Limited | Helicase construct and its use in characterising polynucleotides |
| CA2879261C (en) | 2012-07-19 | 2022-12-06 | Oxford Nanopore Technologies Limited | Modified helicases |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| WO2014040129A1 (en) | 2012-09-12 | 2014-03-20 | The University Of Queensland | Protease-based biosensor |
| AU2014224432B2 (en) | 2013-03-08 | 2019-10-24 | Oxford Nanopore Technologies Limited | Enzyme stalling method |
| GB201314695D0 (en) | 2013-08-16 | 2013-10-02 | Oxford Nanopore Tech Ltd | Method |
| GB201313477D0 (en) | 2013-07-29 | 2013-09-11 | Univ Leuven Kath | Nanopore biosensors for detection of proteins and nucleic acids |
| AU2014274215B2 (en) * | 2013-05-28 | 2019-02-28 | Dcb-Usa Llc | Antibody locker for the inactivation of protein drug |
| US20140364368A1 (en) * | 2013-06-06 | 2014-12-11 | Massachusetts Institute Of Technology | Stimulus responsive nanocomplexes and methods of use thereof |
| WO2015013671A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| EP3044322A4 (en) | 2013-09-12 | 2017-09-06 | The University Of Queensland | Bimolecular protease-based biosensor |
| US20150087810A1 (en) | 2013-09-25 | 2015-03-26 | Cytomx Therapeutics, Inc. | Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof |
| GB201406151D0 (en) | 2014-04-04 | 2014-05-21 | Oxford Nanopore Tech Ltd | Method |
| CN105899678A (zh) | 2013-10-18 | 2016-08-24 | 牛津纳米孔技术公司 | 经修饰的酶 |
| DK3628328T3 (da) * | 2014-01-31 | 2022-12-05 | Cytomx Therapeutics Inc | Matriptase- og u-plasminogen-aktivatorsubstrater og andre spaltelige dele og fremgangsmåder til anvendelse deraf |
| GB201403096D0 (en) | 2014-02-21 | 2014-04-09 | Oxford Nanopore Tech Ltd | Sample preparation method |
| US20170165334A1 (en) * | 2015-12-11 | 2017-06-15 | Tianxin Wang | Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification |
| MX368664B (es) * | 2014-04-29 | 2019-10-10 | Novartis Ag | Células novedosas de vertebrados y métodos para la expresión recombinante de un polipéptido de interés. |
| GB201417712D0 (en) | 2014-10-07 | 2014-11-19 | Oxford Nanopore Tech Ltd | Method |
| EP3137490B1 (en) | 2014-05-02 | 2021-01-27 | Oxford Nanopore Technologies Limited | Mutant pores |
| ES2913205T3 (es) | 2014-05-13 | 2022-06-01 | Bioatla Inc | Proteínas biológicas activas condicionalmente |
| WO2016004383A1 (en) * | 2014-07-03 | 2016-01-07 | City Of Hope | Tumor-selective ctla-4 antagonists |
| EP3172235A2 (en) | 2014-07-25 | 2017-05-31 | Cytomx Therapeutics Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| KR20170042794A (ko) | 2014-09-01 | 2017-04-19 | 브이아이비 브이지더블유 | 돌연변이체 csgg 포어 |
| US10266885B2 (en) | 2014-10-07 | 2019-04-23 | Oxford Nanopore Technologies Ltd. | Mutant pores |
| GB201418159D0 (en) | 2014-10-14 | 2014-11-26 | Oxford Nanopore Tech Ltd | Method |
| WO2016115275A1 (en) | 2015-01-13 | 2016-07-21 | City Of Hope | Ctla4-binding protein peptide-linker masks |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| JP2018520642A (ja) | 2015-05-01 | 2018-08-02 | ジェネンテック， インコーポレイテッド | マスク抗ｃｄ３抗体及びその使用方法 |
| US10736941B2 (en) * | 2015-05-19 | 2020-08-11 | National University Corporation Kumamoto University | Cell membrane-permeating peptide |
| EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| BR102016018074A2 (pt) | 2015-08-07 | 2021-11-16 | ALX Oncology Inc. | Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica |
| SG10201912905VA (en) | 2015-08-07 | 2020-02-27 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| US10758886B2 (en) * | 2015-09-14 | 2020-09-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Conditioned surfaces for in situ molecular array synthesis |
| MA43134A (fr) | 2015-10-30 | 2018-09-05 | Aleta Biotherapeutics Inc | Compositions et méthodes de transduction tumorale |
| CA3002674A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| EP3411077A1 (en) | 2016-02-05 | 2018-12-12 | ImmunoGen, Inc. | Efficient process for preparing cell-binding agent-cytotoxic agent conjugates |
| DK3433280T3 (da) * | 2016-03-22 | 2023-06-19 | Hoffmann La Roche | Protease-aktiverede T-celle-bispecifikke molekyler |
| GB201609220D0 (en) | 2016-05-25 | 2016-07-06 | Oxford Nanopore Tech Ltd | Method |
| WO2018191438A1 (en) | 2017-04-11 | 2018-10-18 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| US20200123227A1 (en) * | 2017-06-20 | 2020-04-23 | The Board Of Regents Of The University Of Texas System | Interferon prodrug for the treatment of cancer |
| CN111278461A (zh) | 2017-08-16 | 2020-06-12 | 百时美施贵宝公司 | 可前药化抗体、其前药以及使用和制备方法 |
| TW201927816A (zh) | 2017-10-14 | 2019-07-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗體、可活化之抗體、雙特異性抗體、和雙特異性可活化之抗體、及其使用方法 |
| WO2019183218A1 (en) | 2018-03-20 | 2019-09-26 | Cytomx Therapeutics, Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| SG11202011349PA (en) | 2018-05-14 | 2020-12-30 | Werewolf Therapeutics Inc | Activatable interleukin-2 polypeptides and methods of use thereof |
| EP3794022A1 (en) | 2018-05-14 | 2021-03-24 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| GB201807793D0 (en) | 2018-05-14 | 2018-06-27 | Oxford Nanopore Tech Ltd | Method |
| JP7477885B2 (ja) | 2018-06-22 | 2024-05-02 | キュージーン インコーポレイテッド | サイトカインをベースとした生理活性化薬剤およびその使用方法 |
| CN112789294A (zh) | 2018-07-24 | 2021-05-11 | 印希比股份有限公司 | 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法 |
| JP7479383B2 (ja) | 2018-09-27 | 2024-05-08 | エクシリオ デベロップメント， インコーポレイテッド | マスクされたサイトカインポリペプチド |
| CN113166261A (zh) | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
| WO2020077257A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| US20210340273A1 (en) | 2018-10-11 | 2021-11-04 | Inhlbrx, inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| CA3121813A1 (en) * | 2018-12-14 | 2020-06-18 | Proviva Therapeutics (Hong Kong) Limited | Il-15 compositions and methods of use thereof |
| WO2020214690A1 (en) * | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| CA3137512A1 (en) | 2019-05-14 | 2020-11-19 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
| AU2020282791A1 (en) | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| US11845801B2 (en) | 2019-06-12 | 2023-12-19 | AskGene Pharma, Inc. | IL-15 prodrugs and methods of use thereof |
| US20220378933A1 (en) * | 2019-09-19 | 2022-12-01 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
| WO2021081258A1 (en) | 2019-10-23 | 2021-04-29 | Cue Biopharma, Inc. | TGF-β POLYPEPTIDES |
| BR112022014667A2 (pt) | 2020-01-29 | 2022-09-20 | Inhibrx Inc | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos |
| US20210252142A1 (en) * | 2020-02-06 | 2021-08-19 | Aetio Biotherapy, Inc. | Compositions and methods for treating viral infections |
| US20210317188A1 (en) | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| CA3174786A1 (en) | 2020-04-10 | 2021-10-14 | Sayantan Mitra | Activatable cytokine constructs and related compositions and methods |
| CA3174130A1 (en) * | 2020-11-23 | 2022-05-27 | Cue Biopharma, Inc. | Tgf-beta polypeptides |
| CA3211924A1 (en) | 2021-03-16 | 2022-09-22 | Sayantan Mitra | Masked activatable cytokine constructs and related compositions and methods |
| AU2022292462A1 (en) * | 2021-06-18 | 2023-12-07 | Nammi Therapeutics, Inc. | FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF |
| WO2023023131A2 (en) * | 2021-08-18 | 2023-02-23 | Werewolf Therapeutics, Inc. | Activatable inteferon polypeptides and methods of use thereof |
| KR20240082350A (ko) | 2021-10-08 | 2024-06-10 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| US20230192798A1 (en) | 2021-10-08 | 2023-06-22 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and combination methods |
| CN118076627A (zh) | 2021-10-13 | 2024-05-24 | 西托姆克斯治疗公司 | 三聚可活化细胞因子构建体以及相关组合物和方法 |
| WO2023183923A1 (en) | 2022-03-25 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
| WO2023192606A2 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| WO2024030858A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| WO2024030843A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| WO2024030847A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| WO2024030850A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| CN116930512B (zh) * | 2023-09-19 | 2024-01-05 | 细胞生态海河实验室 | 一种用于脑卒中再发风险分析的生物标志物及其应用 |
Family Cites Families (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JPS5686121A (en) | 1979-12-14 | 1981-07-13 | Teijin Ltd | Antitumor proten complex and its preparation |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5306731A (en) | 1985-06-14 | 1994-04-26 | Massachusetts Eye And Ear Infirmary | Method and products for treating the eye |
| US5849478A (en) | 1986-08-14 | 1998-12-15 | Cashman; Daniel P. | Blocked-polymerase polynucleotide immunoassay method and kit |
| EP0623679B1 (en) | 1987-05-21 | 2003-06-25 | Micromet AG | Targeted multifunctional proteins |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US4952394A (en) | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5322678A (en) | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
| US5144012A (en) | 1988-08-08 | 1992-09-01 | Eli Lilly And Company | Cytotoxic drug conjugates |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5010176A (en) | 1988-11-10 | 1991-04-23 | Eli Lilly And Company | Antibody-drug conjugates |
| WO1990005749A1 (en) | 1988-11-18 | 1990-05-31 | The Regents Of The University Of California | Conjugated polypeptides and methods for their preparation and use |
| US5162218A (en) | 1988-11-18 | 1992-11-10 | The Regents Of The University Of California | Conjugated polypeptides and methods for their preparation |
| KR0162259B1 (ko) | 1989-12-05 | 1998-12-01 | 아미 펙터 | 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체 |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5272253A (en) | 1991-07-01 | 1993-12-21 | Eli Lilly And Company | Cluster conjugates of drugs with antibodies |
| US6107059A (en) | 1992-04-29 | 2000-08-22 | Affymax Technologies N.V. | Peptide library and screening method |
| WO1994007921A1 (en) | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
| US5834247A (en) | 1992-12-09 | 1998-11-10 | New England Biolabs, Inc. | Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein |
| US6955900B1 (en) | 1993-02-02 | 2005-10-18 | The Scripps Research Institute | Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof |
| US5679548A (en) | 1993-02-02 | 1997-10-21 | The Scripps Research Institute | Methods for producing polypeptide metal binding sites and compositions thereof |
| US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
| GB9322156D0 (en) | 1993-10-27 | 1993-12-15 | Univ Newcastel Upon Tyne | Activation of molecules |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| US5468785A (en) | 1994-04-15 | 1995-11-21 | University Of Akron | Cobaloxime photoinitiated free radical polymerizations |
| NZ291368A (en) | 1994-08-19 | 1999-04-29 | Wallone Region | A compound comprising a marker or a therapeutic agent linked to a ligand containing amino acids wherein the marker or agent is cleaved from the ligand to permit entry into the cell of the marker or agent, medicaments for treating tumours; diagnostic devices |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| WO1996034892A1 (en) | 1995-05-03 | 1996-11-07 | Bioenhancements Ltd. | Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| HU228630B1 (en) | 1996-02-09 | 2013-04-29 | Abbott Biotech Ltd | Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity |
| GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
| US5866341A (en) | 1996-04-03 | 1999-02-02 | Chugai Pharmaceutical Co., Ltd. | Compositions and methods for screening drug libraries |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US5990286A (en) | 1996-12-18 | 1999-11-23 | Techniclone, Inc. | Antibodies with reduced net positive charge |
| ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| WO1998049198A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6265540B1 (en) | 1997-05-19 | 2001-07-24 | The Johns Hopkins University School Of Medicine | Tissue specific prodrug |
| EP0998572A2 (en) | 1997-07-25 | 2000-05-10 | Du Pont Pharmaceuticals Company | Aggrecan degrading metallo proteases |
| US20030027262A1 (en) | 1997-09-18 | 2003-02-06 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| CA2335324A1 (en) | 1998-07-17 | 2000-01-27 | Genetag Technology, Inc. | Methods for detecting and mapping genes, mutations and variant polynucleotide sequences |
| US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| US6203989B1 (en) | 1998-09-30 | 2001-03-20 | Affymetrix, Inc. | Methods and compositions for amplifying detectable signals in specific binding assays |
| US6180343B1 (en) | 1998-10-08 | 2001-01-30 | Rigel Pharmaceuticals, Inc. | Green fluorescent protein fusions with random peptides |
| PL200586B1 (pl) * | 1998-10-16 | 2009-01-30 | Biogen Idec Inc | Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| JP4716578B2 (ja) | 1999-04-12 | 2011-07-06 | ジェネンテック， インコーポレイテッド | 腫瘍壊死因子相同体及びそれをコードする核酸 |
| IL129427A0 (en) | 1999-04-13 | 2000-02-17 | Yeda Res & Dev | Preparation of biologically active molecules |
| BR0010017A (pt) | 1999-04-28 | 2002-06-11 | Univ Texas | Composições e processos para o tratamento de câncer por inibição seletiva de vegf |
| US6268488B1 (en) | 1999-05-25 | 2001-07-31 | Barbas, Iii Carlos F. | Prodrug activation using catalytic antibodies |
| US6903196B1 (en) | 1999-06-17 | 2005-06-07 | Utah Ventures Ii, L.P. | Methods for identifying and isolating tissue-specific lumen-exposed molecules |
| US20040146516A1 (en) | 1999-06-17 | 2004-07-29 | Utah Ventures Ii L.P. | Lumen-exposed molecules and methods for targeted delivery |
| CA2378182C (en) | 1999-07-28 | 2014-09-23 | Genentech, Inc. | Compositions and methods for the treatment of tumors |
| EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US20050208558A1 (en) * | 1999-10-19 | 2005-09-22 | Applera Corporation | Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof |
| DE19952956A1 (de) | 1999-11-03 | 2001-05-17 | Acgt Progenomics Ag | Verfahren zur Verbindung von molekularen Substanzen |
| US6548248B1 (en) * | 1999-11-10 | 2003-04-15 | Propper Manufacturing Co., Inc. | DNA sterilization indicator |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| JP2004507217A (ja) | 2000-04-11 | 2004-03-11 | アンスティテュ・パストゥール | リステリア菌ゲノム、ポリペプチドおよびその使用 |
| US7514067B2 (en) | 2000-04-25 | 2009-04-07 | President And Fellows Of Harvard College | Methods for tumor diagnosis and therapy |
| US20040181830A1 (en) * | 2001-05-07 | 2004-09-16 | Kovalic David K. | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| JP2003534387A (ja) * | 2000-06-01 | 2003-11-18 | ユニべルシテ・カトリック・ドゥ・ルベン | 腫瘍活性化プロドラッグ化合物、並びにこれらの製造方法及び使用方法 |
| EP1286700A2 (en) * | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| US20040014652A1 (en) | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| US6625945B2 (en) | 2000-08-08 | 2003-09-30 | Alfred D. Commins | Balanced, multi-stud hold-down |
| DE10045592A1 (de) | 2000-09-15 | 2002-03-28 | Klaus Pfizenmaier | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
| CA2423850C (en) | 2000-10-09 | 2017-07-04 | Isis Innovation Limited | Therapeutic antibodies |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| EP1349943A2 (en) | 2001-01-04 | 2003-10-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Detection of protein conformation using a split ubiquitin reporter system |
| US7141392B2 (en) | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20040097586A1 (en) | 2001-01-30 | 2004-05-20 | Andre Trouet | Anti-tumor compounds |
| US7132511B2 (en) | 2001-02-19 | 2006-11-07 | Merck Patent Gmbh | Modified anti-EGFR antibodies with reduced immunogenicity |
| US7189830B2 (en) | 2001-02-19 | 2007-03-13 | Merck Patent Gmbh | Anti-KSA/IL-2 fusion proteins with reduced immunogenicity |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| GB0118155D0 (en) | 2001-07-25 | 2001-09-19 | Lorantis Ltd | Superantigen |
| JP2004536877A (ja) * | 2001-07-25 | 2004-12-09 | ロランティス リミテッド | 免疫療法に用いるノッチシグナル伝達モジュレーター |
| ATE462006T1 (de) | 2001-08-01 | 2010-04-15 | Univ Bristol | Isoform des vegfs |
| US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20030134824A1 (en) | 2001-11-12 | 2003-07-17 | Ronald Breslow | Beta-cyclodextrin dimers and phthalocyanines and uses thereof |
| AU2002366303B2 (en) | 2001-12-17 | 2007-09-20 | University College Cardiff Consultants Limited | Enzymatic cleavable reagents for specific delivery to disease sites |
| WO2003068934A2 (en) | 2002-02-14 | 2003-08-21 | Rutter William J | Chimeric molecules for cleavage in a treated host |
| NZ536420A (en) | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| JP4351430B2 (ja) | 2002-10-04 | 2009-10-28 | 財団法人癌研究会 | ナノ黒鉛構造体に結合能を有するペプチド |
| CA2508831C (en) | 2002-12-13 | 2012-05-01 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| CN1548537B (zh) | 2002-12-27 | 2010-05-05 | 深圳市源兴生物医药科技有限公司 | 疫苗制备方法和抗肿瘤疫苗 |
| EP1635858A4 (en) | 2003-05-29 | 2009-08-26 | Scripps Research Inst | TARGETED RELEASE ON CELLS EXPRESSING LEGUMINUM |
| US20050009110A1 (en) | 2003-07-08 | 2005-01-13 | Xiao-Jia Chang | Methods of producing antibodies for diagnostics and therapeutics |
| KR20060069825A (ko) | 2003-08-01 | 2006-06-22 | 제넨테크, 인크. | 제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열 |
| WO2005047461A2 (en) | 2003-08-18 | 2005-05-26 | The Regents Of The University Of California | Polypeptide display libraries and methods of making and using thereof |
| US20050106100A1 (en) | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| US7985401B2 (en) | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US7431915B2 (en) | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| WO2005051315A2 (en) | 2003-11-24 | 2005-06-09 | The Regents Of The University Of California | On-demand cleavable linkers for radioconjugates for cancer imaging and therapy |
| US20060018911A1 (en) | 2004-01-12 | 2006-01-26 | Dana Ault-Riche | Design of therapeutics and therapeutics |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| GB0404187D0 (en) | 2004-02-25 | 2004-03-31 | Biotransformations Ltd | Binding agents |
| EP1579873A1 (en) | 2004-03-23 | 2005-09-28 | Complex Biosystems GmbH | Polymeric prodrugs |
| US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
| US20060234299A1 (en) * | 2004-11-16 | 2006-10-19 | Avidia Research Institute | Protein scaffolds and uses thereof |
| EP1862470A4 (en) | 2005-02-25 | 2010-04-21 | Univ Hokkaido Nat Univ Corp | ELEMENT RETAINED IN BLOOD SHOWING SELECTIVE DEGRADABILITY IN TUMOR TISSUE |
| US7341720B2 (en) | 2005-04-06 | 2008-03-11 | Genzyme Corporation | Targeting of glycoprotein therapeutics |
| DE102005036542A1 (de) | 2005-08-03 | 2007-02-08 | Universität Stuttgart | CTL-Prodrug |
| EP2535346B1 (en) | 2005-08-31 | 2017-08-02 | The Regents of The University of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| WO2007026972A2 (en) | 2005-09-01 | 2007-03-08 | Canon Kabushiki Kaisha | Binding protein molecule |
| JP4567563B2 (ja) | 2005-09-22 | 2010-10-20 | 富士通株式会社 | 携帯端末装置、ヒンジ装置、筒状部材及び光通信システム |
| EP1770099A1 (en) | 2005-09-28 | 2007-04-04 | University of Geneva | Method of producing a modified (poly)peptide |
| AU2006323412A1 (en) | 2005-12-06 | 2007-06-14 | Domantis Limited | Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor |
| GB0604187D0 (en) | 2006-03-02 | 2006-04-12 | Fusion Antibodies Ltd | Peptide and uses thereof |
| CA2645347A1 (en) | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| WO2007106415A2 (en) | 2006-03-10 | 2007-09-20 | Massachusetts Institute Of Technology | Triggered self-assembly conjugates and nanosystems |
| NZ591252A (en) | 2006-03-17 | 2012-06-29 | Biogen Idec Inc | Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids |
| JP4959226B2 (ja) * | 2006-05-19 | 2012-06-20 | 独立行政法人産業技術総合研究所 | スリーフィンガー様蛋白質ライブラリ |
| US8338482B2 (en) * | 2006-07-20 | 2012-12-25 | Wisconsin Alumni Research Foundation | Modulating notch1 signaling pathway for treating neuroendocrine tumors |
| US7700113B2 (en) * | 2006-10-19 | 2010-04-20 | Maine Medical Research Institute, A Division Of Maine Medical Center | Inhibiting breast cancer cell growth by administering an intracellular domain of NOTCH2 |
| ATE542830T1 (de) * | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
| EP2178896A1 (en) | 2007-07-31 | 2010-04-28 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| EP2853267B1 (en) | 2007-09-21 | 2016-12-07 | The Regents of the University of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| NZ586701A (en) | 2008-01-03 | 2013-07-26 | Scripps Research Inst | Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2) |
| WO2010077643A1 (en) | 2008-12-08 | 2010-07-08 | Tegopharm Corporation | Masking ligands for reversible inhibition of multivalent compounds |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| CA2753294A1 (en) | 2009-02-23 | 2010-08-26 | Cytomx Therapeutics, Inc. | Proproteins and methods of use thereof |
-
2010
- 2010-02-23 CA CA2753294A patent/CA2753294A1/en not_active Abandoned
- 2010-02-23 EP EP10744488.7A patent/EP2398494A4/en not_active Withdrawn
- 2010-02-23 WO PCT/US2010/025121 patent/WO2010096838A2/en active Application Filing
- 2010-02-23 BR BRPI1011384A patent/BRPI1011384A2/pt active Search and Examination
- 2010-02-23 CN CN201080017140.XA patent/CN102481341B/zh not_active Expired - Fee Related
- 2010-02-23 US US12/711,199 patent/US8399219B2/en active Active
- 2010-02-23 RU RU2011138951/10A patent/RU2011138951A/ru not_active Application Discontinuation
- 2010-02-23 AU AU2010215761A patent/AU2010215761B2/en not_active Ceased
- 2010-02-23 JP JP2011551304A patent/JP5861223B2/ja active Active
-
2012
- 2012-12-20 US US13/721,528 patent/US8993266B2/en active Active
-
2015
- 2015-03-30 US US14/673,175 patent/US9644016B2/en active Active
- 2015-07-24 JP JP2015146309A patent/JP2015193653A/ja active Pending
-
2017
- 2017-03-10 AU AU2017201682A patent/AU2017201682A1/en not_active Abandoned
- 2017-05-08 US US15/589,464 patent/US10513549B2/en not_active Expired - Fee Related
-
2019
- 2019-11-11 US US16/680,279 patent/US20200308243A1/en not_active Abandoned
-
2022
- 2022-03-21 US US17/699,846 patent/US20230035290A1/en active Pending
- 2022-12-19 US US18/068,104 patent/US20230183308A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012520059A5 (ru) | ||
| RU2011138951A (ru) | Пропротеины и способы их применения | |
| JP7125453B2 (ja) | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 | |
| CN103140236B (zh) | 生长激素多肽及其制备和使用方法 | |
| JP4011914B2 (ja) | キメラポリペプチド、その製造方法、およびその使用 | |
| US10617741B2 (en) | Compositions and methods for oral delivery of therapeutic cargo | |
| CA2304254A1 (en) | Trimerising module | |
| JP2018171063A5 (ru) | ||
| JP2011501951A5 (ru) | ||
| JP2004508828A (ja) | 標的−特異的プロドラッグとしての使用のための抗体サイトカイン−サイトカインインヒビター（セレクトカイン）からの融合タンパク質 | |
| US20240207372A1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| CN115175920A (zh) | 加条形码的xten多肽及其组合物以及其制备和使用方法 | |
| JPWO2021207669A5 (ru) | ||
| CA3180251A1 (en) | Cytokine conjugates | |
| US20160222089A1 (en) | Compositions comprising the nc2 domain of collagen ix and methods of using same | |
| Ekblad et al. | Synthesis and chemoselective intramolecular crosslinking of a HER2‐binding affibody | |
| JPWO2021189139A5 (ru) | ||
| JPWO2021072075A5 (ru) | ||
| CN115867310A (zh) | 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物 | |
| EP0424512A1 (en) | ANTIMETASTATIC PEPTIDES. |